

03-04-05

Ifw

Docket 17652-CON1-CIP1-REI (OCU)



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: VERNON G. WONG et al. ) Examiner:  
Serial Number: 10/820,563 ) Art Unit: 1617  
Filed: September 22, 2004 ) Confirmation No.:  
For: COMPOSITION AND METHOD )  
FOR TREATING GLAUCOMA )  
Irvine, California

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Applicant's provide with regard to the patent application entitled COMPOSITION AND METHOD FOR TREATING GLAUCOMA, filed herewith one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: March 2, 2005

  
Stephen Donovan  
Registration Number 33,433

Please direct all inquiries and correspondence to:

Stephen Donovan  
Allergan, Inc.  
2525 Dupont Drive, T2-7H  
Irvine, California 92623-9534  
Tel: 714.246-4026  
Fax: 714.246-4249

**CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10**

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date March 2, 2005, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV 295681766 US addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Adriane Giberson  
Name of person mailing paper

  
Signature of person mailing paper

Date: March 2, 2005



**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17652-CON1-CIPT-REP(OCU)	SERIAL NO.: 10/820,563
APPLICANT: VERNON G. WONG, et al.	TITLE: COMPOSITION AND METHOD FOR TREATING GLAUCOMA
FILING DATE: SEPTEMBER 22, 2004	GROUP: 1617

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	4,853,224	08/01/1989	WONG	424	427	12/22/1987
	AB	4,997,652	03/05/1991	WONG	424	428	05/31/1989
	AC	5,164,188	11/17/1992	WONG	424	428	11/22/1989
	AD	5,378,475	01/03/1995	SMITH et al.	424	473	02/21/1991
	AE	5,443,505	08/22/1995	WONG et al.	623	4	11/15/1993
	AF	6,217,895	04/17/2001	GUO et al.	424	427	03/22/1999
	AG	6,548,078	04/15/2003	GUO et al.	424	423	12/14/2000
	AH						
	AI						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						
	BC						
	BD						

**OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Cheng, Cheng-Kuo et al., <i>Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis</i> , Investigative Ophthalmology & Visual Science, February 1995, Vol. 36, No. 2, pp. 442-453
	CB	Enyedi, Laura et al., <i>An Intravitreal Device Providing Sustained Release of Cyclosporine and Dexamethasone</i> , Current Eye Research (1995) pp. 549-557
	CC	Hainsworth, Dean P. et al., <i>Sustained Release Intravitreal Dexamethasone</i> , Journal of Ocular Pharmacology and Therapeutics, (1996) Vol. 12, No. 1, pp. 57-63
	CD	Kochinke, F. et al., <i>Biodegradable Drug Delivery System for Uveitis Treatment</i> , Investigative Ophthalmology & Visual Science, February 15, 1996, Vol. 37. No. 3, 186-B98
	CE	
	CF	

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.